Private Capital Group’s Blueprint Medicines BPMC Stock Holding History

Private Capital Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$7K	Sell	131 -129	-50%	-$7.56K	0.01%	1141
2022 Q1	$17K	Sell	260 -162	-38%	-$11.6K	﹤0.01%	1088
2021 Q4	$45K	Sell	422 -184	-30%	-$19.2K	0.01%	732
2021 Q3	$62K	Sell	606 -61	-9%	-$5.68K	0.01%	578
2021 Q2	$59K	Buy	667 +128	+24%	+$11.7K	0.01%	601
2021 Q1	$52K	Sell	539 -7	-1%	-$699	0.01%	623
2020 Q4	$61K	Sell	546 -106	-16%	-$11.2K	0.01%	686
2020 Q3	$60K	Hold	652	–	–	0.01%	632
2020 Q2	$51K	Buy	+652	New	+$44.1K	0.01%	695

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Private Capital Group's BPMC Position: Q2 2022 in Review

Private Capital Group reduced its Blueprint Medicines (BPMC) stake by 50% in Q2 2022, selling an estimated $7.56K and leaving 131 shares worth $7K. The position accounts for 0.01% of the portfolio, ranked #1141.

Private Capital Group first reported a position in BPMC in Q2 2020 and has held it in 9 quarters since. The position peaked at $62K in Q3 2021. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

Private Capital Group held 131 shares of Blueprint Medicines worth $7K as of Q2 2022.
Private Capital Group sold 129 Blueprint Medicines shares in Q2 2022, an estimated $7.56K.
Blueprint Medicines made up 0.01% of Private Capital Group's portfolio in Q2 2022, its #1141 holding.
Private Capital Group first reported a position in Blueprint Medicines in Q2 2020 and has held it in 9 quarters since.
Private Capital Group's Blueprint Medicines position peaked at $62K in Q3 2021.
237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.